.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Argus Health
US Army
Cantor Fitzgerald
Fuji
Teva
Harvard Business School
US Department of Justice
Fish and Richardson
Colorcon

Generated: July 25, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022059

« Back to Dashboard
NDA 022059 describes TYKERB, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from two suppliers. There are seven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TYKERB profile page.

The generic ingredient in TYKERB is lapatinib ditosylate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lapatinib ditosylate profile page.

Summary for NDA: 022059

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details

Pharmacology for NDA: 022059

Mechanism of ActionProtein Kinase Inhibitors

Suppliers and Packaging for NDA: 022059

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TYKERB
lapatinib ditosylate
TABLET;ORAL 022059 NDA Novartis Pharmaceuticals Corporation 0078-0671 0078-0671-19 150 TABLET in 1 BOTTLE (0078-0671-19)
TYKERB
lapatinib ditosylate
TABLET;ORAL 022059 NDA GlaxoSmithKline LLC 0173-0752 0173-0752-00 150 TABLET in 1 BOTTLE (0173-0752-00)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 250MG BASE
Approval Date:Mar 13, 2007TE:RLD:Yes
Patent:► SubscribePatent Expiration:Nov 19, 2021Product Flag?YSubstance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:Jan 8, 2019Product Flag?YSubstance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:Sep 18, 2029Product Flag?YSubstance Flag?YDelist Request?

Expired Orange Book Patents for NDA: 022059

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
TYKERB
lapatinib ditosylate
TABLET;ORAL022059-001Mar 13, 2007► Subscribe► Subscribe
Novartis Pharms Corp
TYKERB
lapatinib ditosylate
TABLET;ORAL022059-001Mar 13, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Medtronic
Citi
Merck
Johnson and Johnson
Chubb
Daiichi Sankyo
Accenture
Julphar
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot